Diosgenin glucoside
(Synonyms: 延龄草苷) 目录号 : GC38408
A steroidal saponin with diverse biological activities
Cas No.:14144-06-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Disogluside is a steroidal saponin that has been found in T. tschonoskii and has diverse biological activities.1,2,3,4,5 It is an inhibitor of UDP-glucuronosyltransferase (UGT) isoform UGT1A4 (IC50 = 10.5 ?M).1 Disogluside is cytotoxic to K562 chronic myeloid leukemia (CML) cells (IC50 = ~7.5 ?M).2 It improves neurological function and decreases neuronal damage in a rat model of spinal cord injury when administered at a dose of 100 mg/kg.3 Disogluside (50 mg/kg) decreases serum levels of glucose, insulin, and triglycerides in diabetic db/db mice.4 It reduces serum malondialdehyde (MDA) levels and stomach myeloperoxidase (MPO) activity in a mouse model of ethanol-induced gastric ulcers.5
1.Xu, M., Dong, P., Tian, X., et al.Drug interaction study of natural steroids from herbs specifically toward human UDP-glucuronosyltransferase (UGT) 1A4 and their quantitative structure activity relationship (QSAR) analysis for predictionPharmacol. Res.110139-150(2016) 2.Liu, M.-J., Wang, Z., Ju, Y., et al.The mitotic-arresting and apoptosis-inducing effects of diosgenyl saponins on human leukemia cell linesBiol. Pharm. Bull.27(7)1059-1065(2004) 3.Chen, X.-B., Wang, Z.-L., Yang, Q.-Y., et al.Diosgenin glucoside protects against spinal cord injury by regulating autophagy and alleviating apoptosisInt. J. Mol. Sci.19(8)2274(2018) 4.Wu, Y., Ye, F., Lu, Y., et al.Diosgenin glucoside protects against myocardial injury in diabetic mice by inhibiting RIP140 signalingAm. J. Transl. Res.10(11)3742-3749(2018) 5.Chen, T., Jiang, W., Zhang, H., et al.Protective effect of trillin against ethanol-induced acute gastric lesions in an animal modelRSC Adv.620081-20088(2016)
| Cas No. | 14144-06-0 | SDF | |
| 别名 | 延龄草苷 | ||
| Canonical SMILES | C[C@@]12[C@]([C@@H]3C)([H])[C@](O[C@]34CC[C@@H](C)CO4)([H])C[C@@]1([H])[C@@](CC=C5[C@@]6(CC[C@H](O[C@]([C@@H]([C@@H](O)[C@@H]7O)O)([H])O[C@@H]7CO)C5)C)([H])[C@]6([H])CC2 | ||
| 分子式 | C33H52O8 | 分子量 | 576.76 |
| 溶解度 | Soluble in DMSO | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7338 mL | 8.6691 mL | 17.3382 mL |
| 5 mM | 0.3468 mL | 1.7338 mL | 3.4676 mL |
| 10 mM | 0.1734 mL | 0.8669 mL | 1.7338 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Diosgenin glucoside provides neuroprotection by regulating microglial M1 polarization
Int Immunopharmacol 2017 Sep;50:22-29.PMID:28623715DOI:10.1016/j.intimp.2017.06.008.
The selective suppression of inflammatory factors in activated microglia, rather than totally inhibiting their activation, might be an effective means of slowing the progression of certain neurodegenerative diseases. Diosgenin glucoside (Dios) is a saponin compound extracted from Tritulus terrestris L. We found that Dios suppressed the synthesis of molecules that promote inflammation (M1 markers, such as NO, IL-6, and TNF-α) in rat microglia and BV-2 cells induced with lipopolysaccharides (LPS). In contrast, Dios had no effects on the cellular production of anti-inflammatory factors (M2 markers, such as IL-10, IL-1Rα and CD206) in LPS and IL-4 treated microglia. Dios repressed IκB-α, ERK MAPK and p38 MAPK phosphorylation, but did not affect JNK in LPS-activated microglia. We also found that conditioned medium obtained from cultures of BV-2 cells incubated with Dios plus LPS was markedly less neurotoxic than conditioned medium obtained from cultures of BV-2 cells incubated with LPS alone. In conclusion, this study demonstrated that Dios can selectively suppress the production/expression of pro-inflammatory M1 markers by activated microglia, without affecting M2 markers, and might provide neuroprotection by regulating microglial M1 polarization. Our results suggest that Dios can be used in treatment of various neuroinflammatory diseases mediated by microglia.
Diosgenin glucoside protects against myocardial injury in diabetic mice by inhibiting RIP140 signaling
Am J Transl Res 2018 Nov 15;10(11):3742-3749.PMID:30662624doi
Myocardial injury is often observed during diabetes, but the nature physiological association is unclear. Here, we investigated the protective effective of Diosgenin glucoside (DG), a pharmacologically active saponin extracted from Tritulus terrestris L., against myocardial injury in type 2 diabetic (db/db) mice and its molecular mechanism of action. Levels of serum and myocardial tissues, blood glucose and inflammatory cytokines, as well as cardiac function indicators, of db/db mice were measured, and DG's mechanism of action was evaluated by immunohistochemistry and Western blotting. We found that long-term DG treatment improved glucose tolerance and lipid profiles, reduced production of IL-1β, IL-6, and TNF-α, and decreased serum levels of the cardiac injury indicators creatine kinase and lactate dehydrogenase. Interestingly, DG also inhibited RIP140 signaling, which normally regulates transcription of estrogen receptor genes and influences expression of proinflammatory cytokines. Our study revealed a novel mechanism of DG's anti-inflammatory effect against myocardial injury via RIP140 signaling modulation in diabetic mice.
Diosgenin glucoside Protects against Spinal Cord Injury by Regulating Autophagy and Alleviating Apoptosis
Int J Mol Sci 2018 Aug 2;19(8):2274.PMID:30072674DOI:10.3390/ijms19082274.
Spinal cord injury (SCI) is a severe traumatic lesion of central nervous system (CNS) with only a limited number of restorative therapeutic options. Diosgenin glucoside (DG), a major bioactive ingredient of Trillium tschonoskii Max., possesses neuroprotective effects through its antioxidant and anti-apoptotic functions. In this study, we investigated the therapeutic benefit and underlying mechanisms of DG treatment in SCI. We found that in Sprague-Dawley rats with traumatic SCI, the expressions of autophagy marker Light Chain 3 (LC3) and Beclin1 were decreased with concomitant accumulation of autophagy substrate protein p62 and ubiquitinated proteins, indicating an impaired autophagic activity. DG treatment, however, significantly attenuated p62 expression and upregulated the Rheb/mTOR signaling pathway (evidenced as Ras homolog enriched in brain) due to the downregulation of miR-155-3p. We also observed significantly less tissue injury and edema in the DG-treated group, leading to appreciable functional recovery compared to that of the control group. Overall, the observed neuroprotection afforded by DG treatment warrants further investigation on its therapeutic potential in SCI.
Phospholipids modulate the substrate specificity of soluble UDP-glucose:steroid glucosyltransferase from eggplant leaves
Phytochemistry 2001 Nov;58(5):663-9.PMID:11672729DOI:10.1016/s0031-9422(01)00292-8.
UDP-glucose-dependent glucosylation of solasodine and diosgenin by a soluble, partially purified enzyme fraction from eggplant leaves is affected in a markedly different way by some phospholipids. While glucosylation of diosgenin and some closely related spirostanols, e.g. tigogenin or yamogenin, is strongly inhibited by relatively low concentrations of several phospholipids, the glucosylation of solasodine is unaffected or even slightly stimulated. These effects depend both on the structure of the polar head group and the nature of the acyl chains present in the phospholipid. The most potent inhibitors of diosgenin glucosylation are choline-containing lipids: phosphatidylcholine (PC) and sphingomyelin (SM) but the removal of phosphocholine moiety from these phospholipids by treatment with phospholipase C results in an almost complete recovery of the Diosgenin glucoside formation by the enzyme. Significant inhibition of Diosgenin glucoside synthesis and stimulation of solasodine glucosylation was found only with PC molecular species containing fatty acids with chain length of 12-18 carbon atoms. PC with shorter or longer acyl chains had little effect on glucosylation of either diosgenin or solasodine. Our results indicate that interaction between the investigated glucosyltransferase and lipids are quite specific and suggest that modulation of the enzyme activity by the nature of the lipid environment may be of importance for regulation of in vivo synthesis of steroidal saponins and glycoalkaloids in eggplant.
Effects of synthetic glycosides on steroid balance in Macaca fascicularis
J Lipid Res 1987 Jan;28(1):1-9.PMID:3559397doi
The predominantly beta-anomer of Diosgenin glucoside (DG) was synthesized and its effects on cholesterol homeostasis were tested in monkeys. Cynomolgus macaques (Macaca fascicularis) were fed, during two 3-week periods, a semipurified diet with 0.1% cholesterol and a similar ration containing 1% DG, respectively. A Chow diet was given for 5 weeks between the experimental periods. Cholesterol and bile acid balance were analyzed during the last week of each semipurified diet. Diosgenin glucoside reduced cholesterolemia from 292 mg/dl to 172 mg/dl, decreased intestinal absorption of exogenous cholesterol from 62.4% to 26.0%, and increased secretion of endogenous cholesterol from -0.8 to 93.5 mg/day. The fecal excretion of neutral steroids rose from 40.7 to 157.3 mg/day; that of bile acids changed, nonsignificantly, from 23.1 to 16.0 mg/day. The cholesterol balance was -44 mg/day in the control period, and 88 mg/day in the DG-fed animals. No toxic signs were observed. Thus, when long-term studies demonstrate that the glucoside is well tolerated, DG and other synthetic glycosides with similar activities may be of use in the management of hypercholesterolemia and atherosclerosis.